PharmaEssentia (FRA:8Z1) Valuation Rank


FRA:8Z1 PharmaEssentia Corp FRA:8Z1
82 GF Score
Price €15.50
GF Value €14.50
! 6 Warning Signs
View Full Analysis

What is PharmaEssentia Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

PharmaEssentia Valuation Rank Related Terms

FRA:8Z1
82GF Score
PharmaEssentia Corp FRA:8Z1
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is PharmaEssentia (FRA:8Z1) Overvalued in 2026?

Based on GuruFocus' analysis, PharmaEssentia stock appears to be overvalued. The current stock price of €15.50 is trading 6.9% above its estimated GF Value™ of €14.50.

Key valuation signals for FRA:8Z1:

  • Valuation Rank:
  • GF Value™: €14.50 vs. price of €15.50 (6.9% above fair value)
  • GF Score™: 82/100 with 6 warning signs

No single metric tells the full story. See the FRA:8Z1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PharmaEssentia Business Description

Other Exchanges 6446:Taiwan
Address 13th Floor, No.3, Park Street, Nangang District, Taipei, TWN, 115
PharmaEssentia Corp engages in medicine discovery, supplements in developing specialty pharmaceutical reagents, API and new drug patterns developments. Its products include BESREMi, Ropeginterferon alfa-2b, Ropeg + anti PD-1, PEG-IL-2, PEG-Cytokines, PD-1-IL-2v, NY-ESO-1 TCR-T, among others. It derives revenue from medicine products sales from contracts with customers.
82GF Score

Get the complete analysis for FRA:8Z1

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€15.50
Price
€14.50
GF Value